These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 30862763)

  • 1. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
    J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
    Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
    Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graves' disease in children: long-term outcomes of medical therapy.
    Rabon S; Burton AM; White PC
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):632-5. PubMed ID: 27169644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.
    Song A; Kim SJ; Kim MS; Kim J; Kim I; Bae GY; Seo E; Cho YS; Choi JY; Cho SY; Jin DK
    Front Endocrinol (Lausanne); 2021; 12():687834. PubMed ID: 34194397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of Graves' hyperthyroidism treated with methimazole.
    Bolaños F; González-Ortiz M; Durón H; Sánchez C
    Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
    Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
    Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X; Shi B; Li H
    Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
    Rittmaster RS; Abbott EC; Douglas R; Givner ML; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years.
    Mussa GC; Corrias A; Silvestro L; Battan E; Mostert M; Mussa F; Pellegrino D
    J Pediatr Endocrinol Metab; 1999; 12(4):537-41. PubMed ID: 10417970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy.
    Kruljac I; Solter D; Vrkljan AM; Solter M
    Endocr Res; 2015; 40(1):25-8. PubMed ID: 24833206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the medical treatment of Graves' disease (GD)].
    Peixoto MC; Coeli CM; Vaisman M
    Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission.
    Konishi T; Okamoto Y; Ueda M; Fukuda Y; Harusato I; Tsukamoto Y; Hamada N
    Endocr J; 2011; 58(2):95-100. PubMed ID: 21206137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease.
    Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N
    Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-partum and non-post-partum relapsing Graves' hyperthyroidism display different response to anti-thyroid drugs.
    Rotondi M; Capelli V; Coperchini F; Pinto S; Croce L; Tonacchera M; Chiovato L
    Eur J Endocrinol; 2018 Jun; 178(6):589-594. PubMed ID: 29559498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug therapy in patients with Graves' hyperthyroidism.
    Tajiri J; Noguchi S; Morita M; Tamaru M; Murakami N; Kato R
    Endocrinol Jpn; 1991 Dec; 38(6):683-7. PubMed ID: 1726635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease.
    Takata K; Amino N; Kubota S; Sasaki I; Nishihara E; Kudo T; Ito M; Fukata S; Miyauchi A
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):845-50. PubMed ID: 19912243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
    García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
    Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.